Recently, the Sinopharm Gene Technology Co., Ltd., jointly invested by China National Pharmaceutical Group Corporation (Sinopharm) and Guangzhou Darui Biotechnology Co., Ltd., was officially settled in the West Taihu Lake Science and Technology Industrial Zone (WEZ).
According to medical statistics, every 20 minutes a baby is born with birth defects in China. At the same time, 80% of cancer patients in China are already in advanced stage when diagnosed, missing the opportunity of effective treatment.
Sinopharm is the largest Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the most complete industrial chain coverage and strongest comprehensive competence in China. In recent years, Sinopharm has successfully developed a gene sequencing technology which is able to accurately determine whether the fetus has a genetic disease only with a small amount of blood drawn from the pregnant woman. This technique can also predict early-stage cancers.
The new project has an investment of 300 million yuan in the first phase, renting a plant of 5,000 square meters in the WEZ. It will establish a research and development center for gene detection reagent, a national distribution center of genetic testing kits, a gene database of birth defects and genetic diseases, a standardized genetic testing laboratory, etc. These facilities will carry out diagnosis of genetic diseases, prenatal diagnosis, diagnosis of single-gene disorders, testing to detect cancers, etc.
掃一掃在手機(jī)打開當(dāng)前頁  |
